Mineralys Therapeutics, Inc.
MLYSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Mineralys Therapeutics, Inc. (MLYS) is listed under Biotechnology. Valued at $2.60B, MLYS is a mid-cap name in its sector. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Market Cap
$2.60B
Beta
0.48
P/E (TTM)
—
P/E (Fwd)
-16.23
EPS (TTM)
$-1.97
EPS (Fwd)
$-1.94
ROE
-31.0%
ROA
-21.3%
Cash
$646.1M
Total Debt
$0
Free CF
-$78.5M
52W Change
100.6%
Annual Financials
Cash vs Debt
Mineralys Therapeutics, Inc. reports $646.1M in cash and $0 in total debt. Free cash flow is running at -$78.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -31.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.48 suggests MLYS is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Mineralys Therapeutics, Inc. and its sector.